PharPoint Research to sponsor Spring 2021 Oncology Investor Conference
PharPoint Research, an award-winning and client-focused contract research organization (CRO), is thrilled to be a CRO Sponsor for the upcoming Spring 2021 Oncology Investor Conference.
About the Oncology Investor Conference
The Spring Meeting of the Oncology Investor Conference will be held from March 29 through April 2, 2021, and feature 4 days of live stream of company presentations and keynote talks, and 5 days of one-on-one meetings.
The event is the preeminent investment event in oncology – for investors seeking to invest in private and public cancer companies, and for cancer related companies seeking investment. The fall and spring meetings have been held every year since 2017.
The Spring 2021 Conference will feature a track on Immunology and COVID-19 Technologies. There will be no other concurrent presentations taking place during the streaming of this track.
About PharPoint
PharPoint Research is an award-winning contract research organization (CRO) with expertise in oncology. Based in Durham, North Carolina, PharPoint offers clinical operations, project management, biostatistics, and data management services to clients of all sizes.
PharPoint’s biometric team has supported 150+ oncology studies since 2007, including 2 successful oncology submissions in the last year. PharPoint’s project managers have extensive experience managing trials of all sizes within oncology from Phase I to Phase IV, with team experience including immuno-oncology, autologous vaccine development, and CAR T-Cell therapy. Additionally, PharPoint’s team is capable of exploiting innovations such as de-centralized clinical trials and patient centric modalities.
As an agile, client-focused CRO, we’ve championed small pharma and biotech companies from day one. Our consultative nature & transparency in both budgets and timelines make us an award-winning partner. PharPoint maintains a business repeat rate of 95%, and can bring clients results faster, with a biometric timeline averaging 31 days faster than the industry standard.